Analysts Anticipate AxoGen, Inc. (NASDAQ:AXGN) to Post -$0.08 EPS
Brokerages expect that AxoGen, Inc. (NASDAQ:AXGN) will post ($0.08) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for AxoGen’s earnings. AxoGen posted earnings of ($0.09) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.1%. The business is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, August 2nd.
According to Zacks, analysts expect that AxoGen will report full year earnings of ($0.33) per share for the current financial year, with EPS estimates ranging from ($0.41) to ($0.28). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.07) per share, with EPS estimates ranging from ($0.21) to $0.02. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover AxoGen.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Thursday, May 4th. The medical equipment provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $12.24 million for the quarter, compared to the consensus estimate of $11.83 million. AxoGen had a negative net margin of 32.05% and a negative return on equity of 155.78%.
Several brokerages have issued reports on AXGN. Cantor Fitzgerald began coverage on shares of AxoGen in a research note on Thursday, June 29th. They issued an “overweight” rating and a $18.00 price objective for the company. ValuEngine raised shares of AxoGen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Wedbush reissued an “outperform” rating and issued a $14.00 price objective (down previously from $17.00) on shares of AxoGen in a research note on Friday, May 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.38.
Several hedge funds have recently bought and sold shares of AXGN. Bank of America Corp DE increased its stake in AxoGen by 8.7% in the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 814 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in AxoGen by 0.9% in the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after buying an additional 93 shares in the last quarter. Campbell & CO Investment Adviser LLC increased its stake in AxoGen by 3.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock valued at $116,000 after buying an additional 341 shares in the last quarter. TFS Capital LLC bought a new stake in AxoGen during the first quarter valued at $120,000. Finally, Knott David M bought a new stake in AxoGen during the first quarter valued at $142,000. 63.73% of the stock is owned by hedge funds and other institutional investors.
AxoGen (AXGN) remained flat at $16.85 on Thursday. 110,795 shares of the company were exchanged. The firm’s 50 day moving average is $15.67 and its 200-day moving average is $12.29. The company’s market cap is $557.65 million. AxoGen has a 12-month low of $6.41 and a 12-month high of $17.25.
ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/20/analysts-anticipate-axogen-inc-nasdaqaxgn-to-post-0-08-eps.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.